	TEST	REPORT	
Reg. No : 2108102015			Reg. Date : 18-Aug-2021
Name : Prabha Tongya			Collected On : 18-Aug-2021 11:13
Age/Sex : 44 Years / Female			Approved On : 18-Aug-2021 14:34
Ref. By			Printed On : 04-Sep-2021 15:54
Client : MEDIWHEEL WELLNESS			
Parameter	<u>Result</u>	<u>Unit</u>	Reference Interval
	KIDNEY FL	JNCTION TEST	
UREA	20.1	mg/dL	10 - 50
UREA (Urease & glutamate dehydrogenase)			10 - 50
(Urease & glutamate dehydrogenase) Creatinine			10 - 50 0.5 - 1.2
(Urease & glutamate dehydrogenase)	20.1	mg/dL	
(Urease & glutamate dehydrogenase) Creatinine	20.1	mg/dL	

----- End Of Report -----

Page 1 of 11

Approved by: DR

DR PS RAO MD Pathologist

This is an electronically authenticated report.

TEST REPORT

Reg. No:2108102015Name:Prabha TongyaAge/Sex:44 Years / FemaleRef. By::Client:MEDIWHEEL WELLNESS

_

 Reg. Date
 : 18-Aug-2021

 Collected On
 : 18-Aug-2021 11:13

 Approved On
 : 18-Aug-2021 12:44

 Printed On
 : 04-Sep-2021 15:54

Parameter	Result	<u>Unit</u>	Reference Interval			
COMPLETE BLOOD COUNT (CBC)						
	SPECIMEN:	EDTA BLOOD				
Hemoglobin	12.6	g/dL	12.0 - 15.0			
RBC Count	4.27	million/cmm	3.8 - 4.8			
Hematrocrit (PCV)	36.5	%	40 - 54			
MCH	29.5	Pg	27 - 32			
MCV	85.5	fL	83 - 101			
MCHC	34.5	%	31.5 - 34.5			
RDW	12.3	%	11.5 - 14.5			
WBC Count	9070	/cmm	4000 - 11000			
DIFFERENTIAL WBC COUNT (Flow	<u>cytometry)</u>					
Neutrophils (%)	55	%	38 - 70			
Lymphocytes (%)	35	%	20 - 40			
Monocytes (%)	06	%	2 - 8			
Eosinophils (%)	04	%	0 - 6			
Basophils (%)	00	%	0 - 2			
Neutrophils	4989	/cmm				
Lymphocytes	3175	/cmm				
Monocytes	544	/cmm				
Eosinophils	363	/cmm				
Basophils	0	/cmm				
Platelet Count (Flow cytometry)	277000	/cmm	150000 - 450000			
MPV	9.8	fL	7.5 - 11.5			
ERYTHROCYTE SEDIMENTATION F	RATE					
ESR (After 1 hour)	7	mm/hr	0 - 21			
Modified Westergren Method						

----- End Of Report ------

Page 2 of 11

This is an electronically authenticated report.



Test done from collected sample

		TEST REPORT	
Reg. No	: 2108102015	Reg.	. Date : 18-Aug-2021
Name	: Prabha Tongya	Colle	ected On : 18-Aug-2021 11:13
Age/Sex	: 44 Years / Female	Арр	roved On : 18-Aug-2021 12:44
Ref. By	:	Print	ted On : 04-Sep-2021 15:54
Client	: MEDIWHEEL WELLNESS		
Paramet	ter	Result	
	Specimer	BLOOD GROUP & RH EDTA and Serum; Method: Haemagglutinati	ion
ABO		'B'	
Rh (D)		Positive	

----- End Of Report ------

This is an electronically authenticated report.

Page 3 of 11



DR PS RAO MD Pathologist

	TES	T REPORT	
Reg. No : 2108102015			Reg. Date : 18-Aug-2021
Name : Prabha Tongya			Collected On : 18-Aug-2021 11:13
Age/Sex : 44 Years / Female			Approved On : 18-Aug-2021 16:31
Ref. By			Printed On : 04-Sep-2021 15:54
Client : MEDIWHEEL WELLNESS			
Parameter	<u>Result</u>	<u>Unit</u>	Reference Interval
	PLASN	IA GLUCOSE	
Fasting Blood Sugar (FBS)	PLASIV <u>112.1</u>	mg/dL	70 - 110
Post Prandial Blood Sugar (PPBS) Hexokinase Method	125.6	mg/dL	70 - 140
Criteria for the diagnosis of diabetes1. HbA1c >/= Or 2. Fasting plasma glucose >126 gm/dL. Fasting is de Or		ake at least for 8 hrs.	
3. Two hour plasma glucose >/= 200mg/dL during an	oral glucose tolerence	e test by using a glucose lo	oad containing equivalent of 75 gm anhydrous glucos

3. Two nour plasma glucose >/= 200 mg/uL during an oral glucose toloron text of dening a glucose toloron text of dening a glucose /= 200 mg/uL dissolved in water.
Or
4. In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose >/= 200 mg/dL.
*In the absence of unequivocal hyperglycemia, criteria 1-3 should be confirmed by repeat testing.
American diabetes association. Standards of medical care in diabetes 2011. Diabetes care 2011;34;S11.

----- End Of Report ------

This is an electronically authenticated report.

Page 4 of 11

		HEMOGLOBIN			
Paramet	ter	<u>Result</u>	<u>Unit</u>	Reference	e Interval
Client	: MEDIWHEEL WELLNESS				
Ref. By	:			Printed On	: 04-Sep-2021 15:54
Age/Sex	: 44 Years / Female			Approved On	: 18-Aug-2021 14:34
Name	: Prabha Tongya			Collected On	: 18-Aug-2021 11:13
Reg. No	: 2108102015			Reg. Date	: 18-Aug-2021
		TEST	REPORT		

Specimen: Blood EDTA

Hb A1C Boronate Affinity with Fluorescent Quenching	5.9	% of Total Hb	Poor Control : > 7.0 % Good Control : 6.2-7.0 % Non-diabetic Level : 4.3-6.2 %	
Mean Blood Glucose	132.74	mg/dL		

Degree of Glucose Control Normal Range:

Poor Control >7.0% *

Good Control 6.0 - 7.0 %**Non-diabetic level < 6.0 %

* High risk of developing long term complication such as retinopathy, nephropathy, neuropathy, cardiopathy, etc.

* Some danger of hypoglycemic reaction in Type I diabetics.

* Some glucose intolerant individuals and "subclinical" diabetics may demonstrate HbA1c levels in this area.

EXPLANATION :-

Total haemoglobin A1 c is continuously symthesised in the red blood cell throught its 120 days life span. The concentration of HBA1c in the cell reflects the average blood glucose concentration it encounters.

*The level of HBA1c increases proportionately in patients with uncontrolled diabetes. It reflects the average blood glucose oncentration over an extended time period and remains unaffected by short-term fluctuations in blood glucose levels. *The measurement of HbA1c can serve as a convenient test for evaluating the adequacy of diabetic control and in preventing various diabetic complications. Because the average half life of a red blood cell is sixty days. HbA1c has been accepted as a measurnment which eflects the mean daily blood glucose concentration, better than fasting blood glucose determination, and the degree of carbohydrate imbalance over the preceding two months.

*It may also provide a better index of control of the diabetic patient without resorting to glucose loading procedures.

HbA1c assay Interferences:

*Errneous values might be obtained from samples with abnormally elevated quantities of other Haemoglobins as a result of either their simultaneous elution with HbA1c(HbF) or differences in their glycation from that of HbA(HbS)

----- End Of Report ------

This is an electronically authenticated report.

Page 5 of 11



DR PS RAO **MD** Pathologist

TEST REPORT

Reg. No:2108102015Name:Prabha TongyaAge/Sex:44 Years / FemaleRef. By:

 Reg. Date
 : 18-Aug-2021

 Collected On
 : 18-Aug-2021 11:13

 Approved On
 : 18-Aug-2021 14:34

 Printed On
 : 04-Sep-2021 15:54

Client : MEDIWHEEL WELLNESS

Printed On	:	04-Se

Parameter	<u>Result</u>	<u>Unit</u>	Reference Interval			
LIPID PROFILE						
Cholesterol (Enzymatic colorimetric)	183.0	mg/dL	Desirable : < 200.0 Borderline High : 200-239 High : > 240.0			
Triglyceride (Enzymatic colorimetric)	126.7	mg/dL	Normal : < 150.0 Borderline : 150-199 High : 200-499 Very High : > 500.0			
VLDL	25.34	mg/dL	15 - 35			
Calculated						
LDL CHOLESTEROL	112.80	mg/dL	Optimal : < 100.0 Near / above optimal : 100-129 Borderline High : 130-159 High : 160-189 Very High : >190.0			
HDL Cholesterol	44.86	mg/dL	30 - 85			
Homogeneous enzymatic colorimet	tric					
Cholesterol /HDL Ratio	4.08		0 - 5.0			
LDL / HDL RATIO Calculated	2.51		0 - 3.5			

Page 6 of 11



		т	EST REPORT		
Reg. No	: 2108102015			Reg. Date	: 18-Aug-2021
Name	: Prabha Tongya			Collected On	: 18-Aug-2021 11:13
Age/Sex	: 44 Years / Female			Approved On	: 18-Aug-2021 14:34
Ref. By	:			Printed On	: 04-Sep-2021 15:54
Client	: MEDIWHEEL WELLNESS				
Paramet	er	Result	<u>Unit</u>	Reference Interval	

NEW ATP III GUIDELINES (MAY 2001), MODIFICATION OF NCEP<?xml:namespace prefix = "o" ns = "urn:schemasmicrosoft-com:office:office" />

LDL CHOLESTEROL CHOLESTEROL HDL CHOLESTEROL
TRIGLYCERIDES
Optimal<100
Desirable<200
Low<40
Normal<150
Near Optimal 100-129
Border Line 200-239
High >60
Border High 150-199
Borderline 130-159
High >240
-
High 200-499
High 160-189

LDL Cholesterol level is primary goal for treatment and varies with risk category and assessment

For LDL Cholesterol level Please consider direct LDL value

Risk assessment from HDL and Triglyceride has been revised. Also LDL goals have changed.

Detail test interpreation available from the lab

All tests are done according to NCEP guidelines and with FDA approved kits. •

• LDL Cholesterol level is primary goal for treatment and varies with risk category and assessment # For test performed on specimens received or collected from non-KSHIPRA locations, it is presumed that the specimen belongs to the patient named or identified as labeled on the container/test request and such verification has been carried out at the point generation of the said specimen by the sender.

KSHIPRA will be responsible Only for the analytical part of test carried out. All other responsibility will be of referring Laboratory. . All other responsibility will be of referring Laboratory.

----- End Of Report ------

Page 7 of 11



		TEST REPORT	
Reg. No:2108102015Name:Prabha TongyaAge/Sex:44 Years / Female			Reg. Date : 18-Aug-2021 Collected On : 18-Aug-2021 11:13 Approved On : 18-Aug-2021 14:34
Ref. By : Client : MEDIWHEEL WELLNES	S		Printed On : 04-Sep-2021 15:54
Parameter	<u>Result</u>	<u>Unit</u>	Reference Interval
	LIVER F	UNCTION TEST WITH	I GGT
Total Bilirubin Colorimetric diazo method	0.31	mg/dL	0.20 - 1.0
Conjugated Bilirubin Sulph acid dpl/caff-benz	0.11	mg/dL	0.0 - 0.3
Unconjugated Bilirubin Sulph acid dpl/caff-benz	0.20	mg/dL	0.0 - 1.1
SGOT (Enzymatic)	13.7	U/L	0 - 31
SGPT (Enzymatic)	11.8	U/L	0 - 31
GGT (Enzymatic colorimetric)	26.0	U/L	7 - 32
Alakaline Phosphatase (Colorimetric standardized method)	52.0	U/L	42 - 141
Protien with ratio Total Protein (Colorimetric standardized method)	7.1	g/dL	6.5 - 8.7
Albumin (Colorimetric standardized method)	4.4	mg/dL	3.5 - 4.94
Globulin Calculated	2.70	g/dL	2.3 - 3.5
A/G Ratio	1.63		0.8 - 2.0

Calculated

----- End Of Report -----

Page 8 of 11



		TEST REPORT	
Reg. No : 2108102015			Reg. Date : 18-Aug-2021
Name : Prabha Tongya			Collected On : 18-Aug-2021 11:13
Age/Sex : 44 Years / Female			Approved On : 18-Aug-2021 12:44
Ref. By			Printed On : 04-Sep-2021 15:54
Client : MEDIWHEEL WELLNESS	6		
Parameter	<u>Result</u>	<u>Unit</u>	Reference Interval
	THY	ROID FUNCTION TES	т
T3 (Triiodothyronine)	1.09	ng/mL	0.87 - 1.78
Chemiluminescence			
T4 (Thyroxine)	8.11	µg/dL	5.89 - 14.9
Chemiluminescence			
TSH (ultra sensitive)	1.174	µIU/mI	0.34 - 5.6

Chemiluminescence

SUMMARY The hypophyseal release of TSH (thyrotropic hormone) is the central regulating mechanism for the biological action of thyroid hormones.TSH is a very sensitive and specific parameter for assessing thyroid function and is particularly suitable for early detection or exclusion of disorders in the central regulating circuit between the hypothalamus, pituitary and thyroid. LIMITATION Presence of autoantibodies may cause unexpected high value of TSH

----- End Of Report ------

Page 9 of 11

This is an electronically authenticated report.

	TEST	REPORT	
Reg. No : 2108102015			Reg. Date : 18-Aug-2021
Name : Prabha Tongya			Collected On : 18-Aug-2021 11:13
Age/Sex : 44 Years / Female			Approved On : 18-Aug-2021 19:14
Ref. By :			Printed On : 04-Sep-2021 15:54
Client : MEDIWHEEL WELLNESS			
Parameter	<u>Result</u>	<u>Unit</u>	Reference Interval
	URINE ROUTIN	NE EXAMINATI	ON
PHYSICAL EXAMINATION			
Quantity	20 cc		
Colour	Pale Yellow		
Appearance	Clear		
CHEMICAL EXAMINATION (BY RE		TRIC METHOD)	50.00
pH Sp. Crowity	5.0		5.0 - 8.0
Sp. Gravity	1.020		1.002 - 1.03
Protein	Nil		
Glucose	Nil		
Ketone Bodies	Nil		
Urine Bile salt and Bile Pigment	Nil		
Urine Bilirubin	Nil		
Nitrite	Nil		
Leucocytes	Nil		
Blood	Nil		
MICROSCOPIC EXAMINATION (MA	NUAL BY MCIROSCOP	<u>Y)</u>	
Leucocytes (Pus Cells)	Nil		
Erythrocytes (Red Cells)	Nil		
Epithelial Cells	1-2/hpf		
Amorphous Material	Nil		
Casts	Nil		
Crystals	Nil		
Bacteria	Nil		
Monilia	Nil		

----- End Of Report ------

Page 10 of 11



		TEST REPORT	
Reg. No	: 2108102015	Reg. Date	: 18-Aug-2021 11:13
Name	: Prabha Tongya	Collected On	: 18-Aug-2021 11:13
Age	: 44 Years / FEMALE	Approved On	: 18-Aug-2021
Ref. By	:	Printed On	: 18-Aug-2021
Client	: MEDIWHEEL WELLNESS		

PAP SMEAR

: Satisfactory
: 00/30/70
:++
: ++
: Absent
: Present
: NIL

Grade	: II inflammatory.
Bethesda category	: NILM(Negative for Intraepithelial Lesion or Malignancy)

Page 11 of 11

This is an electronically authenticated report.



Approved By : DR PS RAO